Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4419338 | 1.00 | LMNA (0.32) | LMNAALDH1A1TP53ALOX15MAPK1 | |
| SCHEMBL4419331 | 1.00 | LMNA (0.32) | LMNAALDH1A1TP53ALOX15MAPK1 | |
| SCHEMBL7228981 | 1.00 | LMNA (0.32) | LMNAALDH1A1TP53ALOX15MAPK1 | |
| SCHEMBL7586456 | 1.00 | LMNA (0.32) | LMNAALDH1A1TP53ALOX15MAPK1 | |
| SCHEMBL115744 | 1.00 | LMNA (0.32) | LMNAALDH1A1TP53ALOX15MAPK1 | |
| SCHEMBL4419340 | 1.00 | LMNA (0.32) | LMNAALDH1A1TP53ALOX15MAPK1 | |
| SCHEMBL215525 | 1.00 | LMNA (0.32) | LMNAALDH1A1TP53ALOX15MAPK1 | |
| SCHEMBL7586461 | 1.00 | LMNA (0.32) | LMNAALDH1A1TP53ALOX15MAPK1 | |
| SCHEMBL4419335 | 1.00 | LMNA (0.32) | LMNAALDH1A1TP53ALOX15MAPK1 | |
| SCHEMBL7228985 | 1.00 | LMNA (0.32) | LMNAALDH1A1TP53ALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1681282-B1 | METHOD FOR PRODUCING 3,3-DIMETHYL-2-(1-PROPENYL) CYCLOPROPANE CARBOXYLATE | SUMITOMO CHEMICAL CO (JP) | 2013-01-23 | — | — | EP | disclosed |
| US-7393971-B2 | Method for producing 3,3-dimethyl-2-(1-propenyl) cyclopropanecarboxylate | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-07-01 | — | — | US | disclosed |
| US-20070078278-A1 | Method for producing 3, 3-dimethyl-2-(1-propenyl) cyclopropanecarboxylate | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1681282-A1 | METHOD FOR PRODUCING 3,3-DIMETHYL-2-(1-PROPENYL) CYCLOPROPANE CARBOXYLATE | Sumitomo Chemical Company, Limited (JP) | 2006-07-19 | — | — | EP | disclosed |
| EP-0939073-B1 | Ester of 2,2-dimethyl-cyclopropanecarboxylic acid and their use as pesticides | SUMITOMO CHEMICAL CO (JP) | 2002-12-04 | — | — | EP | disclosed |
| US-6225495-B1 | PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-05-01 | — | — | US | disclosed |
| EP-0939073-A1 | Ester of 2,2-dimethyl-cyclopropanecarboxylic acid and their use as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078278-A1 | Method for producing 3, 3-dimethyl-2-(1-propenyl) cyclopropanecarboxylate | AOC3, PDXK, AIPL1 | LMNA 2611/4885ALDH1A1 92/4885TP53 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.